Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 500 million

Vinge has advised ABG Sundal Collier as arranger in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 500 million under the existing framework of SEK 2 billion.
April 24, 2026

Vinge advises GBL on its acquisition of BUKO Group

Vinge, together with Latham & Watkins, advises Groupe Bruxelles Lambert (“GBL”) (Euronext Brussels: GBLB) on its acquisition of BUKO Group, a leading platform in temporary traffic management, from funds advised by Equistone Partners Europe and the founding family, while management will re-invest alongside GBL. The transaction, which is subject to customary approvals, will entail a EUR 0.5 billion equity investment by GBL.
April 24, 2026

Vinge advise Lagercrantz Group on the business acquisition of FMK Trafikprodukter

Lagercrantz Group, through its subsidiary Nordic Road Safety, has entered into an agreement to acquire the business and assets of FMK Trafikprodukter – a niche company specialising in CE-certified road barrier systems for the Swedish and Nordic infrastructure market.
April 24, 2026